Author: Xia, Guozhi; Qin, Bowen; Ma, Chaoran; Zhu, Yaowu; Zheng, Qiangsun
Title: High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study Cord-id: d3llzamz Document date: 2021_9_9
ID: d3llzamz
Snippet: Background: Cardiac injury is common and associated with poor clinical outcomes in COVID-19. Data are lacking whether high-dose intravenous vitamin C (HIVC) could help to ameliorate myocardial injury in the pandemic. Methods: The retrospective cohort study included consecutive severe and critically ill COVID-19 patients with cardiac injury receiving symptomatic supportive treatments alone or together with HIVC. Troponin I and inflammatory markers were collected at admission and day 21 during hos
Document: Background: Cardiac injury is common and associated with poor clinical outcomes in COVID-19. Data are lacking whether high-dose intravenous vitamin C (HIVC) could help to ameliorate myocardial injury in the pandemic. Methods: The retrospective cohort study included consecutive severe and critically ill COVID-19 patients with cardiac injury receiving symptomatic supportive treatments alone or together with HIVC. Troponin I and inflammatory markers were collected at admission and day 21 during hospitalization from the electronic medical records. Results: The patients (n = 113) were categorized into the ameliorated cardiac injury (ACI) group (n = 70) and the non-ameliorated cardiac injury (NACI) group (n = 43). Overall, fifty-one (45.1%) patients were administered with HIVC, the percentages of patients with HIVC were higher in the ACI group than those in the NACI group. Logistic regression analysis revealed that HIVC was independently associated with the improvement of myocardial injury. Further analysis showed that inflammatory markers levels significantly decreased at day 21 during hospitalization in patients with HIVC therapy compared to those administered with symptomatic supportive treatments alone. Meanwhile, similar results were also observed regarding changes in inflammatory markers levels from baseline to day 21 during hospitalization in the patients treated with HIVC. Conclusions: HIVC can ameliorate cardiac injury through alleviating hyperinflammation in severe and critically ill patients with COVID-19.
Search related documents:
Co phrase search for related documents- acute respiratory failure and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory failure and administration receive: 1
- acute respiratory failure and administration time: 1, 2
- acute respiratory failure and admission illness onset: 1
- acute respiratory failure and admission illness onset time: 1
- acute respiratory failure and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory failure and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute respiratory failure and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- adjuvant therapy and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adjuvant therapy and logistic regression analysis: 1, 2, 3
- adjuvant therapy and lung damage: 1, 2
- administration time and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- administration time and logistic regression analysis: 1, 2, 3, 4
- administration time and long administration time: 1, 2
- administration time and lung damage: 1, 2
- admission illness onset and logistic regression: 1, 2, 3, 4, 5, 6
- admission illness onset and logistic regression analysis: 1
- admission illness onset time and logistic regression: 1, 2
- admission obtain and logistic regression: 1
Co phrase search for related documents, hyperlinks ordered by date